Study Summary
This trial is testing the safety of SHetA2, a potential new cancer treatment, in patients with recurrent cervical, ovarian, or endometrial cancer.
- Cervical Cancer
- Ovarian Cancer
- Endometrial Cancer
Treatment Effectiveness
Study Objectives
2 Primary · 10 Secondary · Reporting Duration: up to three years
Trial Safety
Trial Design
1 Treatment Group
SHetA2 capsule
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: SHetA2 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are additional volunteers being sought for this research endeavor?
"Indeed, according to clinicaltrials.gov the study is actively recruiting participants after being initially posted on June 27th 2022 and recently edited on July 7th 2022. The trial needs 50 volunteers from a single location for completion." - Anonymous Online Contributor
Has SHetA2 been granted authorization by the Food and Drug Administration?
"The safety of SHetA2 was rated a 1 on the scale due to it being in Phase 1 trials, and thus having sparse evidence regarding its effectiveness and potential side effects." - Anonymous Online Contributor
How many participants have been recruited for this experiment?
"Affirmative. Clinicaltrials.gov states that this medical trial is recruiting patients, which began on June 27th 2022 and was most recently updated on July 7th 2022. The study requires the recruitment of 50 individuals from a single site to participate in its research operations." - Anonymous Online Contributor